Partial
Partially Aligned
Patient Risk:
Moderate
Summary
Some claims match the DIPRIVAN (propofol) FDA label excerpts (e.g., approved adult ICU sedation and MAC; hypotension/respiratory depression/pain at injection site and hypersensitivity are generally consistent). However, multiple important claims are unsupported or not aligned with the provided label excerpt set, including pediatric ICU sedation, PRIS characterization, manufacturer/pricing/recall assertions, and omission/mismatch of label-specific contraindications (egg/soy) and pediatric use limitations.
Category Scores
Accurate Statements
Propofol is used for the induction and maintenance of general anesthesia in adults and children.
Supported for general anesthesia induction/maintenance with pediatric age limitations stated (induction ≥3 years; maintenance ≥2 months). Adult use implied by label indication categories. (Indications and Usage section 1; Limitations of Use).
Propofol is used for monitored anesthesia care.
Supported: MAC sedation in adult patients (Indications and Usage section 1).
Propofol is used for sedation in intensive care units (ICUs) for patients requiring mechanical ventilation.
Supported: ICU sedation of intubated, mechanically ventilated adult patients (Indications and Usage section 1).
Common side effects of propofol injection include hypotension.
Supported: Hypotension and/or bradycardia listed among serious/important adverse reactions. (Adverse Reactions section 6; also Warnings/Precautions 5.12/5.8 context).
Hypersensitivity reactions are a risk associated with propofol injection.
Supported: Hypersensitivity reaction listed among serious/important adverse reactions; contraindication also reflects hypersensitivity. (Adverse Reactions section 6; Contraindications section 4).
Healthcare professionals carefully monitor patients for these adverse events during administration.
Partially supported: label requires continuous monitoring and describes monitoring for early signs of hypotension/cardiovascular depression; also continuous monitoring for hypotension/bradycardia. (Dosage and Administration 2.1; Warnings/Precautions 5.8; 5.12).
Propofol infusion syndrome (PRIS) is rare but potentially fatal.
Supported as “associated with… that have resulted in death” for ICU sedation and described as a serious risk; rarity is not explicitly stated in the provided excerpts. (Warnings/Precautions 5.9).
Unsupported Statements
Propofol is supplied by Fresenius Kabi, Hikma Pharmaceuticals, and Teva Pharmaceuticals.
Not supported by the provided DIPRIVAN label excerpts (sections 1–17 including the provided indications/dosing/safety excerpts do not list suppliers for propofol products).
Fresenius Kabi, Hikma Pharmaceuticals, and Teva Pharmaceuticals provide propofol in various formulations and dosages for intravenous administration.
Not supported by provided label excerpts (dosage forms list only DIPRIVAN vial strengths; no company-to-formulation mapping provided).
Other companies that manufacture or distribute propofol injection include Fresenius Helios, B. Braun Medical, and Baxter Healthcare.
Not supported by provided DIPRIVAN label excerpts.
The availability of propofol can be influenced by manufacturing schedules and market demand.
Not supported by provided DIPRIVAN label excerpts.
Pricing for propofol injection can vary based on the supplier, dosage, quantity purchased, and geographic location.
Not supported by provided DIPRIVAN label excerpts.
Recalls or safety alerts related to propofol injection can occur due to manufacturing defects, contamination, or packaging issues.
Not supported by provided DIPRIVAN label excerpts.
Common side effects of propofol injection include respiratory depression.
Not supported in the provided label excerpts; the excerpts highlight apnea requiring ventilatory support during induction and “undesirable cardiorespiratory depression,” but “respiratory depression” as a common side effect is not stated in the provided text.
Common side effects of propofol injection include pain at the injection site.
Not supported by the provided label excerpts.
Propofol infusion syndrome (PRIS) is a more serious risk associated with propofol injection.
The label describes PRIS as a serious risk associated with ICU sedation and resulting in death; however, “more serious risk” is not a phrasing used/supported explicitly in the provided excerpts.
Patents for the original compound propofol have long expired.
Not supported by provided DIPRIVAN label excerpts.
Patents may exist for specific formulations, delivery systems, or manufacturing processes related to propofol injection.
Not supported by provided DIPRIVAN label excerpts.
Contradictions
Low
AI Statement
Propofol is used for sedation in intensive care units (ICUs) for patients requiring mechanical ventilation.
Label Reference
The label supports ICU sedation only for intubated, mechanically ventilated adult patients; it also states DIPRIVAN is not indicated for pediatric ICU sedation. The claim as written does not specify adults and could be read as broader. (Indications and Usage section 1; Limitations of Use and Pediatric Use 8.4).
Low
AI Statement
Propofol is used for the induction and maintenance of general anesthesia in adults and children.
Label Reference
Label limits pediatric induction to patients ≥3 years and maintenance to ≥2 months, and does not recommend below those ages due to established safety/effectiveness gaps. The claim does not reflect these age limits. (Indications and Usage section 1; Limitations of Use).
Important Omissions
Egg/soy-related contraindications: DIPRIVAN is contraindicated in patients with a history of anaphylaxis to eggs, egg products, soybeans or soy products, and in those with known hypersensitivity to propofol/components. The AI claims hypersensitivity risk but omits the specific contraindications.
Importance:
Moderate
Pediatric limitations: DIPRIVAN is not indicated for pediatric ICU sedation and not indicated for MAC sedation in pediatric patients; safety/effectiveness not established for those uses. The AI describes ICU sedation and MAC without the pediatric exclusions.
Importance:
High
PRIS risk factors/thresholds and required immediate discontinuation when signs develop (e.g., high-dose/prolonged infusions >5 mg/kg/hour for >48 hours; discontinue immediately when signs develop). The AI states PRIS is serious/rare/fatal but omits these actionable label details.
Importance:
High
Administration precautions in label: do not use if aggregation/phase separation; inspect for particulate/discoloration; single-dose only preparation/discard; not to mix with other agents; continuous infusion and slow initiation in ICU to titrate and minimize hypotension; avoid abrupt discontinuation. The AI only broadly says monitoring is careful, omitting key administration instructions.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Potential risk arises from pediatric population misrepresentation/omission (AI does not reflect that DIPRIVAN is not indicated for pediatric ICU sedation or pediatric MAC sedation per label) and omission of label-specific PRIS details and contraindications. Other claims (hypotension/hypersensitivity risk) are broadly consistent.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
Yes |
| Promotes Unapproved Use |
Yes |
| Hallucination Risk |
Medium |
Recommendation
Partially Aligned
Primary Issue
Pediatric use limitations and ICU/MAC scope are not accurately reflected (omission of “not indicated” statements), and several non-label business claims (suppliers/pricing/recalls/patents) are unsupported. Key safety details (PRIS thresholds/actions and egg/soy contraindications) are omitted.
Suggested Improvement
Limit indications statements to the label’s specified age groups and adult-only requirements for ICU sedation (intubated, mechanically ventilated adults) and MAC sedation in adults; explicitly state “not indicated” for pediatric ICU and pediatric MAC per label. Include key contraindications (egg/soy anaphylaxis and propofol/component hypersensitivity) and PRIS warning details (risk factors and immediate discontinuation when signs develop). Remove unsupported claims about manufacturers, pricing, market availability, recalls, and patent status unless supported directly by the label provided.